Fertility preservation is an important issue for young women diagnosed with breast cancer. The most well-established options for fertility preservation in cancer patients, embryo and oocyte cryopreservation, have not been traditionally offered to breast cancer patients as estradiol rise during standard stimulation protocols may not be safe for those patients. Potentially safer stimulation protocols using tamoxifen and aromatase inhibitors induce lower levels of estradiol whereas similar results in terms of number of oocyte and embryo obtained to standard protocols. Cryopreservation of immature oocytes and ovarian cortical tissue, both still experimental methods, are also fertility preservation options for breast cancer patients.
to undergo adjuvant systemic chemotherapy which will threaten their future fertility. A 5-year, or longer, course of adjuvant endocrine therapy with tamoxifen is recommended for patients with endocrine-sensitive tumors. Although tamoxifen therapy is not in itself gonadotoxic, it may delay the possibility of pregnancy in some older women whose fertility is naturally diminished and thus reduce the likelihood that these women will conceive.
More than 80% of women below the age of 40 years suffering from breast cancer are successfully treated today. Given this high rate of survival, it is fitting that these issues in breast cancer patients should focus on the quality of life including reproductive potential, which is threatened by cancer treatment.
Fertility Preservation Options for Women With Breast Cancer

COUNSELING THE PATIENT
Fertility issues have been recognized of great importance for young women diagnosed with breast cancer and other malignancies during their reproductive years. 2, 3 According to the American Society of Clinical Oncology guidelines for fertility preservation in cancer patients, 4 oncologists should be prepared to discuss the implications of chemotherapy on fertility with their patients as early as possible during cancer treatment planning or alternatively refer patients to reproductive specialists to discuss the probability of iatrogenic ovarian failure and possible fertility-preservation options. It is imperative that patients receive timely and accurate information but unfortunately only one-third of breast cancer patients recall discussions regarding the impact of treatment on their future fertility. 5 The incidence of breast cancer increases with age, therefore, delaying childbearing to later in life results in more female cancer patients expressing an interest in fertilitypreservation options.
The most well-established methods for fertility preservation are embryo and oocyte cryopreservation. These procedures both require ovarian stimulation which usually takes 2 weeks from the beginning of the menstrual cycle to complete. Typically, there is a gap of 4 to 6 weeks between women undergoing breast cancer surgery and the commencing of chemotherapy, therefore, often sufficient time is available to undergo ovarian stimulation. There are, however, particular issues that need to be highlighted with regard to fertility preservation in breast cancer patients, including the impact of breast cancer therapy on future fertility, the potential deleterious effect of supraphysiologic estrogen levels on breast malignancies, the particular difficulties when counseling carriers of BRCA mutations who may need to undergo oophorectomy later in life, and the potential risks of subsequent pregnancy in former breast cancer patients.
IMPACT OF BREAST CANCER TREATMENT ON FERTILITY
Gonadal toxicity by chemotherapy agents varies largely depending on the age of the patient, the type of agent, number of cycles, and cumulative dose. Chemotherapy causes depletion of the primordial follicle pool in a drug and dose-dependent manner. The most cytotoxic group of chemotherapy substances to the female gonad includes alkylating agents such as cyclophosphamide, which is currently used for treatment of breast cancer. Although most chemotherapy agents target dividing cells, cyclophosphamide is not cell cycle specific and can damage the resting primordial follicles which comprise the ovarian reserve.
Amenorrhea rates after therapies including cyclophosphamide vary. For example, in the breast cancer CMF protocol (cyclophosphamide, methotrexate, and 5-fluorouracil), 20% to 70% of women below 40 years of age at the time of treatment experience amenorrhea but this can rise to as high as 100% if women are older. 6 The more recently introduced adjuvant chemotherapy regimens as AC (anthracycline and cyclophosphamide) seem to have a lower incidence of amenorrhea. It is thought that this is related to a lower cumulative dose of cyclophosphamide reached with this protocol, although data is not yet conclusive. Anthracycline-based regimens present also with a variable incidence of amenorrhea from 0% to 96% depending on whether patients are below or above 30 years of age, respectively. 7 The further addition of taxanes to anthracycline regimens for the treatment of early-stage breast cancer has not shown a further increase in risk of amenorrhea in breast cancer patients when paclitaxel was used but in protocols including docetaxel, doxorubicin, and cyclophosphamide, the risk of amenorrhea increased from 33% to 51%. 8 As seen in most studies, the risk of ovarian failure after chemotherapy is clearly dependent on a patient's age. Younger patients have a greater follicle reserve in their ovaries than older women and therefore, are more likely to retain some ovarian function after a chemotherapeutic insult. Table 1 summarizes the clinical benefits from adjuvant therapy in breast cancer patients and the impact of these therapies on future fertility.
BREAST CANCER SUSCEPTIBILITY GENE CARRIERS
Most hereditary breast cancers are attributed to autosomal dominant germ-line mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) and this group of patients accounts for up to 10% of women with breast cancer. It is Fertility Preservation in Breast Cancer 755 estimated that, in the general population, 1 in every 1000 women is a carrier of BRCA mutations with an increased incidence to up to 2.5% in certain ethnic groups, such as people with Jewish-Ashkenazi origin. Women with BRCA1 gene mutations have a 50% to 80% lifetime risk of breast cancer with an increased risk for presenting with bilateral breast cancer and also at a young age. BRCA1 gene mutations carriers have also a 40% to 60% risk of ovarian cancer and patients are usually offered prophylactic bilateral mastectomy to reduce the risk of a contralateral breast cancer and prophylactic bilateral salpingo-oophorectomy around the age of 40 years to reduce the risk of ovarian cancer but in some cases also to reduce the risk of breast cancer. Carriers of BRCA2 mutations present with similar features although with a lesser risk for ovarian cancer, which also presents at older age than in BRCA1 carriers. Hysterectomy is not usually performed in these patients and although there is still the possibility of carrying a pregnancy to term, some may prefer to have a gestational carrier.
Consequently, the presence of a BRCA gene mutation in a breast cancer patient interested in fertility preservation is a complex issue. Investigation of treatments for infertility in a large population series of BRCA mutation carriers has revealed no association between the risk of breast cancer and exposure to fertility drugs which is a reassuring information. 10 In contrast, in a recent study of breast cancer patients undergoing ovarian stimulation for fertility preservation, the presence of a BRCA1 mutation was associated with a significantly lower response to stimulation and occult primary ovarian insufficiency. 11 Breast cancer patients with BRCA mutations undergoing fertility preservation may transmit increased cancer risks to their offspring. If the patients are concerned by this risk, preimplantation genetic diagnosis after thawing of cryopreserved embryos may be useful for selection of the embryos appropriate for transfer.
POTENTIAL RISK OF A SUBSEQUENT PREGNANCY IN BREAST CANCER SURVIVORS
Pregnancy after breast cancer does not seem to increase the risk of recurrence or to adversely affect maternal outcome. Moreover, no increased risk for congenital malformations in children conceived after completion of chemotherapy has been found.
Pregnancy is associated with a reduced risk for death in women who had breast cancer earlier. 12 However, breast cancer survivors who become pregnant may be a self-selected group and may not be representative of the larger population of women as those having a high risk of tumor recurrence may have chosen not to get pregnant. Timing a pregnancy after a diagnosis of breast cancer is also a complex issue but in general, patients are advised to delay pregnancy attempts for at least 2 years after the diagnosis, mainly because the risk of recurrence is greatest during this period. For patients prescribed tamoxifen, pregnancy is usually considered safe after completion of the 5-year treatment period. Tamoxifen has a similar structure of diethylstilbestrol, and pregnancy while on tamoxifen treatment is discouraged because of the potential teratogenic effects of this drug during pregnancy.
Although a pregnancy is considered safe for most breast cancer survivors, gestational surrogacy may be suitable for breast cancer survivors with high risk for recurrence or who have to be on lifelong therapy with tamoxifen or aromatase inhibitors. In women with BRCA1 or 2 gene mutations, the risk of pregnancy is less well established. A gestational carrier may be indicated in patients who have undergone salpingo-oophorectomy with the aim of reducing endogenous estrogen 756
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FERTILITY-PRESERVATION OPTIONS FOR BREAST CANCER PATIENTS
For women with a partner or those wishing to use a sperm donor, embryo cryopreservation after in-vitro fertilization (IVF) is considered an established fertility preservation method. It is routinely used worldwide for surplus embryos after infertility treatments and it has been used for more than 20 years. Live birth rates after transfer of embryos which are intact after thaw have the same implantation potential as fresh embryos and they can lead to a 59% pregnancy rate and a 26% live birth rate. 13 For single cancer patients without a partner and those not wishing to use a sperm donor, freezing mature or immature oocytes, although still experimental, is the only option. 14 To obtain mature oocytes, ovarian stimulation must be performed and therefore, a delay of 2 to 6 weeks may be necessary. Cryopreservation of mature oocytes using vitrification techniques to avoid ice crystal formation has become a very effective method to store oocytes in recent years and the success rates of fertilization post-thaw and pregnancy rates have increased significantly close to those of current IVF with fresh oocytes. 15 The clinical outcome of oocyte cryopreservation depends on many factors including the original quality of the retrieved oocytes, the freezing protocol, and each stage of handling of the oocytes.
When there is not enough time or the patient does not wish to undergo an ovarian stimulation treatment, alternative approaches include the retrieval of oocytes without ovarian stimulation and the cryopreservation of ovarian cortex. Retrieved immature oocytes may be cryopreserved at an immature stage or after in-vitro maturation. 14 This option is limited as only a few fertility centers worldwide offer treatments by using this technique. The cryopreservation of immature oocytes is still experimental and requires optimization; however, this method has resulted in live births. 16 Encouragingly, it has been shown that immature oocytes survive cryopreservation better than mature oocytes; after thawing, these oocytes can be successfully matured in vitro and fertilized.
Ovarian tissue cryopreservation for future transplantation is a new promising method for fertility preservation, which is discussed in a separate chapter of this issue. With regard to breast cancer patients, the risk for metastatic ovarian involvement is extremely unlikely in early stages of the disease and the procedure is considered today as safe for breast cancer patients. 17, 18 In 2 recent reports, the histologic evaluation of fresh or frozenthawed cortical tissue of breast cancer patients undergoing cryopreservation of ovarian tissue did not evidence any metastases. 19, 20 
STIMULATION PROTOCOLS FOR OOCYTE OR EMBRYO CRYOPRESERVATION IN WOMEN WITH BREAST CANCER
Epidemiologic and experimental data indicates that estrogen plays a central role in the initiation and promotion of breast tumorigenesis. Circulating estradiol levels are elevated during conventional ovulation induction for IVF. The rise in estradiol is directly proportional to number of follicles recruited to grow, therefore, alternative and potentially safer protocols have been introduced for fertility preservation for breast cancer patients including natural cycle IVF, stimulation protocols with tamoxifen alone or combined with gonadotropins, and stimulation protocols with aromatase inhibitors to reduce the estrogen production. Natural cycle IVF do not give more than 1 oocyte or embryo per cycle and has a high rate of cycle cancellation. The cycle may thus result ineffective when a chemotherapy Fertility Preservation in Breast Cancer 757 treatment is imminent and the patient may not have a chance for a second cycle of IVF treatment.
TAMOXIFEN
Tamoxifen is a nonsteroidal triphenylethylene compound related to clomiphene. Tamoxifen was initially shown to be as effective as clomiphene in ovarian stimulation of anovulatory patients in the early 1970s. However, tamoxifen was later identified as a selective estrogen receptor modulator as it has demonstrable antiestrogenic actions on breast tissue with the inhibition of growth of breast tumors by competitive antagonism of estrogen at its receptor site. Tamoxifen has been used in treatment and prevention of estrogen receptor-positive breast cancer for nearly 3 decades and it is accepted as first-line drug in hormonal treatment of breast cancer. 21 Tamoxifen may be used for ovulation induction alone starting on day 2 to 3 or 5 of the menstrual cycle in doses of 20 to 60 mg/d, or in combination with low-dose gonadotropins, similar to the use of clomiphene when given alone or combined with gonadotropins for IVF. It has been shown that ovarian stimulation using tamoxifen for fertility preservation in cancer patients can increase the mature oocyte and embryo yield when compared with natural cycle IVF (1.6 vs. 0.7, P = 0.03 and 1.6 vs. 0.6, P = 0.02, respectively) and reduce cycle cancellations. 22 The combined protocol with tamoxifen and gonadotropins for IVF has shown to further increase the number of oocytes and embryos for cryopreservation (5.1 vs. 1.5, P = 0.001 and 3.8 vs. 1.3, P = 0.001, respectively). 23 Studies with tamoxifen showed that its' short use for ovulation induction does not adversely affect oocyte and embryo development. 24 Even though peak estradiol levels in ovarian stimulation with tamoxifen on day of human chorionic gonadotropin (hCG) administration may be significantly higher than in women undergoing natural cycle IVF, the effects of estrogen on breast tissue are blocked at the receptor sites.
AROMATASE INHIBITORS
Aromatase inhibitors are being used in the treatment of breast cancer in postmenopausal women for more than 30 years. Aromatase, a product of CYP19 gene, is a cytochrome P450 enzyme complex that catalyzes the conversion of androstendione and testosterone to their respective estrogenic products estrone and estradiol. CYP19 is highly expressed in granulosa cells of ovarian follicles, where its expression depends on cyclical gonadotropin stimulation. Aromatase is not only present in the ovary and many other extragonadal tissues including adipose tissue and but breast also have aromatization of androgens to estrogens.
The third-generation aromatase inhibitors developed in the 1990s, anastrozole and letrozole, are drugs of choice for the treatment of breast cancer in women with receptor-positive metastatic breast cancer. Their use has also been introduced as new treatment option for ovulation induction. They are potent and highly selective by competitively binding the active site of the enzyme complex. Letrozole suppresses plasma estradiol, estrone, and estrone sulfate levels significantly at doses of 0.1 to 5 mg/d.
Inhibition of the aromatase system increases gonadotropin production by releasing the hypothalamic-pituitary axis from estrogenic negative feedback.
Ovulation induction with aromatase inhibitors has been described in clomipheneresistant patients with polycystic ovarian syndrome. 25 Aromatase inhibitors have a relatively short life of about 40 hours, therefore, the effects on the pituitary are not long-lasting and down-regulation of the pituitary does not occur when their administration is discontinued. Consequently, the adverse effects observed with clomiphene on endometrial growth and cervical
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Rodriguez-Wallberg and Oktay www.clinicalobgyn.com secretion are avoided with aromatase inhibitors. Available data indicates a significantly higher pregnancy and delivery rates in anovulatory women stimulated with aromatase inhibitors than with clomiphene. 26 Use of letrozole alone for ovarian stimulation has been associated with lower estrogen levels than those of the natural cycle. 27 Data on the use of anastrozole for ovarian stimulation in anovulatory women, however, is more limited and studies so far do not support its use over clomiphene. 26 
COMBINED STIMULATION PROTOCOLS WITH LETROZOLE AND GONADOTROPINS
Combined stimulation protocols with etrozole and gonadotropins have produced comparable results to standard IVF whereas decreasing gonadotropin requirements, which seem to be cost-effective. Combined letrozole and gonadotropin protocols have also shown significantly lower peak estradiol levels than standard IVF (278.9 pg/mL vs. 483.4 pg/mL, Pr0.001), which may be more suitable for breast cancer patients. 28 Our stimulation protocol for embryo and oocyte cryopreservation with letrozole in combination with gonadotropins (controlled ovarian stimulation treatment with letrozole supplementation study, COST-LESS) 23 has not shown any detrimental effects in breast cancer recurrence after short-term follow-up. 29 Combined anastrozole and gonadotropins protocols have shown comparable results to COST-LESS regarding number of oocytes and embryos obtained, but significantly higher peak estradiol levels than in the COST-LESS (1325.89 pg/mL vs. 427.78 pg/mL). 30 Therefore, we currently prefer the COST-LESS protocol for women with breast cancer undergoing fertility preservation for embryo and oocyte cryopreservation. Figure 1 illustrates the COST-LESS protocol. Letrozole is commenced orally on the second or third day of the menstrual cycle at a dose of 5 mg/d. After 2 days of letrozole administration, 150 to 300 IU/d of recombinant follicle-stimulating hormone or human menopausal gonadotropin are added depending on patient's age and antral follicle counts on day 2 or 3.A gonadotropin-releasing hormone (GnRH) antagonist is added when estradiol levels exceed 250 pg/mL (918 pmol/L) or the leading follicle reach 14 mm in diameter to prevent premature luteinizing hormone (LH) surge. Patients are monitored with ultrasound and estradiol levels, folliclestimulating hormone, and LH measurements every 1 to 2 days until oocyte retrieval. To obtain a high oocyte maturation rate, oocyte maturation is triggered Fertility Preservation in Breast Cancer 759 when at least 2 leading follicles reach a diameter of 20 mm 28 and oocyte retrieval is performed 36 hours after the trigger. In the original protocol, we used hCG to trigger the final maturation of oocytes. However, hCG has a longer half-life compared with endogenous LH, and it may further increase estradiol production even after egg retrieval. We have recently improved the COST-LESS protocol by triggering egg maturation with a GnRH analog (GnRHa), which resulted in significantly decreased estradiol levels on the day of retrieval and a faster drop of estradiol levels in the subsequent days. 31 In that study, the GnRHa trigger was also associated with lower incidence of ovarian hyperstimulation syndrome, indicating that GnRHa had a suppressive effect on estrogen production after trigger. 31 Letrozole is reinitiated after oocyte retrieval to prevent a rebound increase of estradiol levels (Fig. 1 ). Monitoring of estradiol levels is repeated 3 days after oocyte retrieval and if the levels are higher than 250 pg/mL, letrozole is continued until estradiol levels fall below 50 pg/mL (183.5 pmol/L) and then discontinued.
COST-LESS protocols in breast cancer patients are associated with a 44% reduction in gonadotropin requirements and treatment costs and with similar fertility outcomes than after high-dose gonadotropin treatment for IVF in terms of oocyte and embryo yield and of fertilization rates. 28 However, up to 12% to 20% of oocytes for IVF treatments may be expected to be immature. To further increase the yield of mature oocytes and embryos for fertility preservation in breast cancer patients, we have recently introduced in-vitro maturation as a complementary strategy when immature oocytes were also retrieved in stimulated cycles with aromatase inhibitors combined with gonadotropins. 32 The follow-up of 79 breast cancer patients (mean age 36 ± 3.8 y) having undergone fertility preservation with COST-LESS protocols has not shown to increase the hazard ratio recurrence when compared with controls who did not undergo fertility preservation after a mean followup of 2 years. 29 Although the time lapse between surgery and chemotherapy in patients who underwent fertility preservation was significantly longer (45 d vs. 33 d, P = 0.01) and one of the concerns with ovarian stimulation before breast cancer chemotherapy is the delay in the initiation of treatment; there was no difference in terms of recurrence rate and relapse-free survival between breast cancer patients who underwent ovarian stimulation with COST-LESS and controls. 29 Furthermore, data from large studies have shown no effect on survival or recurrence if chemotherapy is initiated within 12 weeks after surgery. 33, 34 Although peak estradiol levels in the COST-LESS protocol are maintained close to the levels of the natural cycle (405.9 ± 256.6 pg/mL or 1486.7 ± 942.1 pmol/L), 29 longer follow-up of breast cancer patients having undergone fertility preservation with COST-LESS, tamoxifen, and other stimulation protocols are still needed.
Aromatase inhibitors are contraindicated during pregnancy. However, data indicates that fertility treatment with letrozole is safe and its use before conception does not seem to have increased risks for the fetus. In a retrospective analysis of data from 5 centers in Canada, the overall incidence of congenital malformations and chromosomal abnormalities was similar among children born after fertility treatments with clomiphene (4.8%) or letrozole (2.4%). In fact, the incidence of major malformations was significantly higher after fertility treatments with clomiphene than with letrozole (3% vs. 1.2%, respectively). 35 Of note, when aromatase inhibitors are used for fertility preservation and IVF, the embryos are never exposed to the drug as they are not transferred in that treatment cycle.
Summary
In conclusion, fertility preservation is often possible for most breast cancer patients.
There is still a need to increase the awareness with fertility-preservation techniques so that patients are referred as early as possible after the initial diagnosis is made. For those undergoing oocyte or embryo freezing, potentially safer stimulation protocols have been proposed.
